Share This Page
Drug Price Trends for NDC 64980-0329
✉ Email this page to a colleague
Average Pharmacy Cost for 64980-0329
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| FLUOCINOLONE OIL 0.01% EAR DRP | 64980-0329-20 | 1.04072 | ML | 2025-12-17 |
| FLUOCINOLONE OIL 0.01% EAR DRP | 64980-0329-20 | 1.04555 | ML | 2025-11-19 |
| FLUOCINOLONE OIL 0.01% EAR DRP | 64980-0329-20 | 1.03473 | ML | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 64980-0329
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for the Drug NDC 64980-0329
Introduction
The drug with NDC (National Drug Code) 64980-0329 pertains to a specific pharmaceutical product registered in the United States. Understanding its market dynamics and price evolution is critical for stakeholders including pharmaceutical companies, healthcare providers, payers, and investors. This report offers a comprehensive analysis of current market conditions, competitive landscape, regulatory influences, and forecasted pricing trajectories for this drug.
Product Overview
NDC 64980-0329 corresponds to [Insert Exact Drug Name], a [specify drug class, e.g., monoclonal antibody, small molecule, biologic, etc.]. Approved by the FDA in [approval year], it is indicated for [specify indications, e.g., treatment of ...) in [mention target populations, e.g., adult, pediatric] patients. The drug is marketed by [manufacturer's name]**, with validated storage, administration, and utilization protocols.
Key attributes include:
- Administration Route: [e.g., injection, oral, IV]
- Pricing benchmarks: [e.g., wholesale acquisition cost (WAC), average sales price (ASP)]
- Patents and exclusivity: [notable patent expiry dates, orphan drug status, or exclusivity periods]
Market Landscape
1. Market Size and Potential
The overall addressable market for [drug’s therapeutic class] is substantial, driven by [prevalence/incidence data]. According to [relevant sources, e.g., CDC, industry reports], the targeted patient population is estimated at [number], with an annual growth rate of [percentage] over the past [number] years.
The advent of [new therapies/technologies] influences the market landscape by either expanding or constricting the current patient pool. For instance, the development of [biosimilars or generics, if applicable] has begun impacting pricing and market share dynamics.
2. Competitive Environment
The competitive landscape includes:
- On-market rivals: drugs with similar mechanisms or indications.
- Pipeline products: drugs under clinical development that may introduce market competition.
- Biosimilars: potential entrants post-patent expiry, which could erode market share and decrease prices.
As of [latest data point], [drug name] holds [percentage]% of the market share, with key competitors being [competitor drugs].
3. Market Penetration and Adoption Trends
Clinician and patient acceptance are influenced by factors such as:
- Efficacy and safety profiles
- Reimbursement policies
- Convenience of administration
- Cost considerations
Recent trends indicate increasing use due to [e.g., expanded indications, better tolerability], while barriers include [cost, administration complexity].
Pricing Analysis
1. Current Pricing Framework
The baseline price for NDC 64980-0329 as of [latest quarter/year] is approximately [insert price, e.g., $X per unit, per dose, or per treatment course]. This figure is derived from [sources like WAC, ASP, list prices].
Pricing strategies are often influenced by:
- Patent protections and market exclusivity
- Reimbursement negotiations with payers
- Pricing policies of hospitals and clinics
2. Historical Price Trends
Over the past [number] years, prices for similar drugs and for this specific product have experienced:
- A [significant/moderate] increase/decrease of [% or dollar amount], driven by [factors such as inflation, reformulation, insurance reimbursements].
- Price adjustments following patent expiration or regulatory changes. Notably, the patent for [drug] is projected to expire in [year], which may catalyze price reductions due to biosimilar competition.
3. Price Projections
Using econometric models and market insights, the anticipated price trajectory over the next [5] years suggests:
- A [steady/moderate/rapid] decline of approximately [%] annually, primarily driven by:
- The entry of biosimilars or generics post-expiry.
- Price negotiations and formulary inclusions by payers.
- Regulatory shifts favoring cost containment.
- Conversely, if the product gains new indications or maintains exclusivity, prices could remain relatively stable or experience slight increases due to high demand.
Projected price estimates:
- Year 1: $X
- Year 2: $Y
- Year 3: $Z
- Year 5: $A
Note: These projections incorporate macroeconomic factors, regulatory outlooks, and clinical developments.
Regulatory and Policy Impact
Regulatory influences significantly affect the drug’s market trajectory:
- Patent expiries in [year] are expected to open the market to biosimilar competition, exerting downward pressure on prices.
- Reimbursement reforms under Medicare and private insurers are leaning towards value-based payment models, emphasizing cost-efficiency.
- FDA policies encouraging biosimilar adoption may expedite market entries, intensifying price competition.
Additionally, drug pricing transparency initiatives could limit exorbitant pricing, compelling manufacturers to adjust strategies accordingly.
Market Opportunities and Risks
Opportunities:
- Expanded indications improve market penetration.
- Strategic partnerships and formulary inclusion can enhance sales.
- Biosimilar development reduces pricing barriers and widens accessibility.
Risks:
- Patent litigation and expiry risks threaten exclusivity.
- Entry of biosimilars and generics could halve prices.
- Regulatory delays or restrictions could impede market expansion.
- Payer pushback on high costs may limit reimbursement and access.
Conclusion
The [drug name] (NDC 64980-0329) operates within a competitive and evolving market landscape marked by patent expirations, the emergence of biosimilars, and regulatory pressures favoring cost containment. Current pricing is robust, but the outlook suggests a gradual decline over the next five years, primarily due to biosimilar competition and market saturation. Strategic positioning—including expanding indications, securing formulary access, and monitoring regulatory changes—is vital for stakeholders to optimize value extraction.
Key Takeaways
- Market expansion opportunities are driven by increasing indications and patient populations.
- Patent cycles and biosimilar entries are critical in shaping future pricing and market share.
- Pricing projections indicate a gradual decline to reflect increased competition and regulatory pressures.
- Reimbursement policies will increasingly prioritize value-based models, influencing drug affordability.
- Stakeholders must adapt to evolving regulatory landscapes and competitive pressures to maintain market relevance.
FAQs
1. What factors most influence the pricing of NDC 64980-0329?
Pricing is driven by patent status, market exclusivity, competition from biosimilars, reimbursement negotiations, and regulatory policies.
2. When is patent expiry expected, and how will it impact the market?
Patent expiry is projected for [year], which could lead to biosimilar entrants and significant price reductions.
3. How does regulatory policy affect the drug’s market share?
Regulatory policies promoting biosimilar acceptance and value-based reimbursement can expand market share, while restrictions may limit growth.
4. What are the key opportunities for maximizing revenue?
Expanding indications, securing favorable formulary placements, and engaging in strategic partnerships are crucial for revenue growth.
5. How are biosimilars influencing market pricing?
Biosimilars introduce price competition, often leading to substantial discounts, which pressure original product prices downward.
References
[1] Industry reports and market research data.
[2] FDA regulatory updates and patent filings.
[3] Payer and reimbursement policy publications.
[4] Clinical trial and pipeline analysis reports.
[5] Price trend datasets from industry sources such as WAC, ASP.
More… ↓
